Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Healthcare Biotechnology
Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and... see more

Recent & Breaking News (TSX:ONC)

Oncolytics Biotech(R) to Present at the 21st Annual BIO CEO & Investor Conference

Accesswire February 4, 2019

Oncolytics Biotech® Announces First Patient Treated in Study Combining Pelareorep, Carfilzomib and the Checkpoint Inhibitor Opdivo® in Multiple Myeloma

GlobeNewswire December 12, 2018

Oncolytics Biotech® Announces Increased PD-L1 Expression When Combining Pelareorep with a Proteasome Inhibitor in Poster Presentation at the 60th American Society of Hematology Annual Meeting & Exposition

GlobeNewswire December 3, 2018

Oncolytics Biotech® Announces Appointment of Rita Laeufle, M.D., as Chief Medical Officer

GlobeNewswire November 29, 2018

Oncolytics Biotech® Announces First Patient Treated in Phase 2 Study Combining Pelareorep and Keytruda® in Advanced Pancreatic Cancer

GlobeNewswire November 26, 2018

Oncolytics Biotech® Announces Attendance of Upcoming Conferences

GlobeNewswire November 13, 2018

Oncolytics Biotech® Reports 2018 Third Quarter Financial Results and Provides Corporate Update

GlobeNewswire November 12, 2018

Oncolytics Biotech® Announces Presentation at the Society for Immunotherapy of Cancer 2018 Annual Meeting Showcasing Upregulation of PD-L1 Expression with Reovirus Infection

GlobeNewswire November 9, 2018

Oncolytics Biotech® to Host Conference Call to Discuss Third Quarter Financial Results and Corporate Highlights

GlobeNewswire November 5, 2018

Oncolytics Biotech® Announces Abstract for ASH Annual Meeting & Exposition Demonstrating Pelareorep Increases PD-L1 Expression When Combined with a Proteasome Inhibitor

GlobeNewswire November 1, 2018

Oncolytics Biotech® Establishes New At-The-Market Facility

GlobeNewswire October 24, 2018

11 Stocks That Moved From ESMO 2018

Benzinga.com  October 22, 2018

Oncolytics Biotech® Announces Positive Clinical Trial Results for Pelareorep in Patients with KRAS Mutant Metastatic Colorectal Cancer for Presentation at ESMO 2018

GlobeNewswire October 22, 2018

Oncolytics Biotech® Announces Publication of Positive Clinical Results for Pelareorep in Abstract for ESMO 2018 Congress

GlobeNewswire October 11, 2018

The Daily Biotech Pulse: Novartis Blood Disorder Drug Improves Patient Outcomes, Audentes To Offer Shares

Benzinga.com  October 10, 2018

Oncolytics Biotech® Announces a Publication Demonstrating That Intravenously Delivered Oncolytic Viruses Effectively Target Tumors Even in the Presence of Neutralizing Antibodies

GlobeNewswire October 2, 2018

Oncolytics Biotech® Enters into Common Stock Purchase Agreement for up to US$26 Million with Lincoln Park Capital, LLC

GlobeNewswire September 28, 2018

Oncolytics Biotech® to Present at the Ladenburg Thalmann 2018 Healthcare Conference

GlobeNewswire September 26, 2018

Oncolytics Biotech® Provides Corporate and Clinical Update

GlobeNewswire September 19, 2018

Oncolytics Biotech® Announces Investigator Sponsored Multiple Myeloma Study Combining REOLYSIN® and Nivolumab (Opdivo®) with Standard of Care

GlobeNewswire September 17, 2018